China Pharma HoldingSTU:XQJ 26 PB Ratio is 33.92 as of Jul. 11, 2026, which is 5118% above its 10-year median of 0.65. GuruFocus rates STU:XQJ with a GF Score™ of 26/100 and a GF Value™ of €10.05. The stock has 3 warning signs investors should review. Among 919 Drug Manufacturers companies, China Pharma Holding ranks better than 85.85% on this metric.
The historical rank and industry rank for China Pharma Holding's PB Ratio or its related term are showing as below:
STU:XQJ'
s PB Ratio Range Over the Past 10 Years
Min: 0.11 Med: 0.65 Max: 6.48
Current: 0.7
During the past 13 years, China Pharma Holding's highest PB Ratio was 6.48. The lowest was 0.11. And the median was 0.65.
STU:XQJ's PB Ratio is ranked better than 85.85% of 919
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs STU:XQJ: 0.70
During the past 12 months, China Pharma Holding's average Book Value Per Share Growth Rate was -57.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -62.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -59.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -48.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of China Pharma Holding was 54.20% per year. The lowest was -66.50% per year. And the median was -23.80% per year.
Back to Basics: PB Ratio
China Pharma Holding (STU:XQJ) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
China Pharma Holding PB Ratio Related Terms
China Pharma Holding PB Ratio Historical Data
* Premium members only.
The historical data trend for China Pharma Holding's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Pharma Holding PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's PB Ratio distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
China Pharma Holding (STU:XQJ) has a PB Ratio of 33.92 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China Pharma Holding and its competitors. This is 5118% above median its historical median of 0.65. Over the past decade, China Pharma Holding's PB Ratio has ranged from 0.11 to 6.48. According to the industry distribution chart, China Pharma Holding ranks #130 out of 919 companies in the Drug Manufacturers industry, placing it in the top 14.1%.
Is China Pharma Holding's PB Ratio too high?
China Pharma Holding's current PB Ratio of 33.92 is 5118% above median its 10-year median of 0.65. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 6.48. The Drug Manufacturers industry median PB Ratio is 1.90. China Pharma Holding's value of 33.92 is 1685.3% above this industry median. Based on the distribution chart, China Pharma Holding ranks #130 out of 919 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Pharma Holding has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's PB Ratio compare to TXMD and RMTI?
According to the Drug Manufacturers industry distribution chart, China Pharma Holding ranks #130 out of 919 companies for PB Ratio. This places China Pharma Holding in the top 14% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.90. China Pharma Holding's value of 33.92 is 1685.3% above this benchmark. Historically, China Pharma Holding's own PB Ratio has ranged from 0.11 to 6.48 over the past decade. While the company's 10-year median is 0.65 vs. the industry median of 1.90, China Pharma Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Pharma Holding's current PB Ratio of 33.92 is 1685.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China Pharma Holding and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Pharma Holding's current PB Ratio is 33.92, which is 5118% above median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
China Pharma Holding (STU:XQJ) has a current PB Ratio of 33.92. The stock's GF Value™ is €10.05, compared to a current price of €26.80 — trading 166.7% above its estimated fair value. The current PB Ratio is 33.92, which is 5118% above median its 10-year median of 0.65 and 1685.3% above the Drug Manufacturers industry median of 1.90. China Pharma Holding's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For China Pharma Holding (STU:XQJ), the current PB Ratio is 33.92 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Pharma Holding (STU:XQJ) Overvalued in 2026?
Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued.
The current stock price of €26.80 is trading 166.7% above its estimated GF Value™ of €10.05.
Key valuation signals for STU:XQJ:
PB Ratio: 33.92 (5118% above median its 10-year median of 0.65)
GF Value™: €10.05 vs. price of €26.80 (166.7% above fair value)
Industry Position: 1685.3% above the Drug Manufacturers median (#130 of 919)
No single metric tells the full story. See the STU:XQJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score
Get the complete analysis for STU:XQJ
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:XQJ has been successfully added to your 
